UK medical science is in for a major payday from LifeArc, a British-based medical research charity, which has sold some of the rights to Keytruda, one of the world’s biggest-selling cancer drugs. Back in 2007, the research charity penned a collaboration with Organon (bought by Merck in 2009) to humanize the antibody-based therapy; now, it’s sold some of those royalty rights over to the Canada Pension Plan Investment Board (CPPIB), getting about £1 billion ($1.3 billion) in the process. This cashing-in sees LifeArc instantly become one of the UK’s leading medical research charities by size of its investment assets. Source: Fierce Biotech 20/5/2019